Category — Innovation(RnD)

Israel, India Agree to Promote Homeopathy

During the Israeli Prime Minister Benjamin Netanyahu‘s visit to India in January, India and Israel signed a memorandum of understanding to enhance cooperation and boost research in homeopathy, a system of alternative medicine.

The agreement to collaborate is between India’s Central Council for Research in Homeopathy, the Ministry of AYUSH, and Israel’s Center for Integrative Complementary Medicine at the Shaare Zedek Medical Center, Jerusalem.

homeopathic meds

The MoU will also establish a joint working group.

February 7, 2018   No Comments

Scientists from India Develop World’s Thinnest Material

Indian scientists at the Indian Institute of Technology, Gandhinagar, in the state of Gujarat, have  claimed  to have created the world’s thinnest material, 100,000 times narrower than a sheet of paper — a two-dimensional material of just one-nanometer thickness. The three member research team includes two students working toward a PhD: Harini Gunda, and Saroj Kumar Das; and Professor Kabeer Jasuja, a Ph.D. from Kansas State University.

“We prepared boron-rich nanosheets by an extremely simple method, which merely involves dissolving a boride compound in water and letting it recrystallize for just the right duration of time,” Dr. Kabeer Jasuja of the university’s Department of Chemical Engineering explained. “The rich chemistry of boron is expected to make these nanosheets useful for not only storing energy but also for generating energy in a green way. We are now working towards utilizing these nanosheets for developing the next generation batteries and nanocatalysts,” added Jasuja.

Ball-and-stick model of the crystal structure of magnesium diboride

Ball-and-stick model of the crystal structure of magnesium diboride

Boron has long been a topic of interest to researchers due to its properties: low density, high mechanical strength, high thermal resistance, high melting point, its ability to absorb neutrons, and its high resistance to chemical attacks.


February 6, 2018   No Comments

Pfizer, India’s Council of Medical Research to Address Antimicrobial Resistance

New York City-based Pfizer and state owned Indian Council of Medical Research (ICMR) have partnered to establish a center in New Delhi to combat antimicrobial resistance in India. The joint initiative will implement a series of comprehensive interventions, ranging from programs for training staff in the healthcare sector to scaling up surveillance networks, and creating awareness around the responsible use of antibiotics. Pfizer has provided an initial grant of  $1 million  for this initiative with a provision to scale up as the program expands.

Logo of Indian Council of Medical Research

“It is important to channel all necessary resources in developing, implementing and monitoring antibiotic resistance to minimize its adverse impact, which is posing a huge threat to both health and food security. Infections such as pneumonia and tuberculosis are becoming difficult to treat due to decreased effectiveness arising out of the irrational usage of antibiotics,” said K. VijayRaghavan, secretary, Department of Health Research and director general, ICMR.

Recognizing antimicrobial resistance as an important area to tackle, the government finalized a National Action Plan on Antimicrobial Resistance last year which recommends six strategic priorities including improving awareness through communication, education and training, strengthening surveillance, and promoting investments for initiatives in this project.

January 31, 2018   No Comments

Western Union Launches India R&D, Tech Center

Englewood, CO-headquartered financial services and communications company, Western Union, announced the launch of its Western Union Technology Engineering Center (WUTEC) in Pune, 75 miles east of Mumbai, in the state of Maharashtra, India. The new research center will serve as Western Union’s innovation and engineering hub in the region.  It will focus on developing and building technology aimed at improving digital retail customer experiences around the globe.

“Innovation is hardwired in our DNA. As the company that invented the concept of digitizing money, Western Union is uniquely positioned at the intersection of money and technology. WUTEC India will join our other key technology centers across the world to expand the reach of our omnichannel platform, integrating our digital efforts with our iconic physical agent network to serve a vast global customer base,” said Hikmet Ersek, president and CEO of Western Union.

Picture of cash, calculator and laptop

“On the anniversary of 25 years of our service in India, this is a fitting start to a new chapter. We are extremely proud to have connected Indian diaspora from nearly every country in the world by enabling money movement to their families and loved ones,” added Ersek. “Over this time frame, Western Union has formalized money movement into urban, semi-urban and rural India, giving millions of consumers the assurance of receiving cash or money deposited directly into millions of bank accounts. This new tech center is the continuation of our transformation journey.”

January 31, 2018   No Comments

Biocon India Receives US FDA Approval for Biosimilar

India’s Bangalore-based Biocon Ltd is the country’s first company to have a “biosimilar” approved in the U.S. for Roche’s drug Trastuzumab, marketed as Herceptin, and used in treating certain breast and stomach cancers.

Biocon Ltd.

Kiran Mazumdar-Shaw, the company’s chairperson and managing director said, “This was the first biosimilar for Herceptin approved by the US FDA. It was a proud milestone for us because there are competitors, including Pfizer, Merck and Amgen, with deeper pockets and more experience in developing and selling biologics, which says a lot about what our scientists have done. It’s recognition that India has the skills to develop such complex molecules. It puts India on the global map of biosimilars.”

The biosimilar, which will be sold under the brand name Ogivri, brings Biocon a step closer to building a truly original bio-drug, or ‘novel biologic’ for various markets. Biocon already has two novel biologics—Nimotuzumab for treating head and neck cancer and Itolizumab for treating psoriasis—that it markets in India, added Mazumdar-Shaw.

January 30, 2018   No Comments